Among a high portion of male patients with bladder cancer and expressing AR, the combination of AR inhibitor, Enzalutamide, and CDDP synergistically inhibited bladder cancer cell growth more effectively than single agent alone [37]. Here, AR is linked to urinary bladder carcinoma.